The anti-obesity drug Zepbound made by Eli Lilly & Co. could be one of the biggest cost drivers for health insurers and ...

As expected by many, Eli Lilly And Co (NYSE:LLY) filed a motion to intervene as a defendant in a case between the Outsourcing ...

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, ...

and Eli Lilly’s drug is more potent, and perhaps negotiations with national health services will also make it more ...

Eli Lilly’s Zepbound drug holds potential to dominate the global obesity market due to its superior efficacy and strategic ...

After plugging billions into its manufacturing network to meet rampant demand for Mounjaro and Zepbound, Eli Lilly is looking ...

According to a recent release from GlobalData, Eli Lilly’s obesity offering could become a potential leader in the market.

Patients also face long waitlists to meet with obesity medicine specialists who can prescribe the drugs to them, a problem ...

Given Wegovy’s success and record-high sales, a wave of investments has gone into the obesity space over the last couple of ...

The Food and Drug Administration approved Eli Lilly’s weight-loss drug Zepbound on Dec. 27 to treat sleep apnea, a common but ...

The United States Food and Drug Administration says the shortage of Eli Lilly’s Zepbound and Mounjaro ... with Zepbound being approved to treat obesity and Mounjaro being approved for diabetes.

The lawsuit was brought against the FDA after the agency declared an end to the shortage that allowed pharmacies to sell compound versions of the popular weight loss drugs, but Eli Lilly said it ...